HUTCHMED (China) Limited ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
14analysts covering
FY Revenue (est.)
$606.4Mnext fiscal year
FY EPS (est.)
$0.16next fiscal year
Monitoring Framework
Key Performance Indicators
Oncology/Immunology Consolidated Revenue Annually285.5MTarget: $330 million to $450 million
FRUZAQLA (fruquintinib ex-China) In-Market Sales by Takeda Annually366.2MTarget: Continued global commercial expansion and launch in new territories
ELUNATE (fruquintinib in China) In-Market Sales Annually100.1MTarget: Sustained domestic market recovery and growth
Watch Items
- Regulatory review of Sovleplenib (HMPL-523) for Immune Thrombocytopenic Purpura (ITP) in ChinaTrigger: NMPA approval decisionAction: Monitor regulatory announcements and prepare for commercial launch in China
- Topline results of the SAFFRON Global Phase III trial of ORPATHYS (savolitinib) and TAGRISSO combinationTrigger: Data readout expected in H2 2026Action: Evaluate efficacy and safety data to support global regulatory filings
- Clinical progression of the Antibody-Targeted Therapy Conjugate (ATTC) platform candidates (HMPL-A251, HMPL-A580, HMPL-A830)Trigger: Initiation of Phase I trials or partnership agreementsAction: Assess early safety/efficacy signals and potential outbound licensing deals with multinational pharma
Research as of 20 Jun 2026